메뉴 건너뛰기




Volumn 21, Issue , 2014, Pages 93-97

How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer

Author keywords

Abiraterone; Cabazitaxel; Castration resistant prostate cancer; Docetaxel; Enzalutamide; Radium 223

Indexed keywords

CANCER VACCINE;

EID: 84921525984     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (9)

References (21)
  • 1
    • 49649115490 scopus 로고    scopus 로고
    • Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostatespecific antigen, pain, and quality of life response and survival in the TAX-327 study
    • Berthold D, Pond G, Roessner M, de Wit R, Eisenberger M, Tannock I. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostatespecific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008;14(9):2763-2767.
    • (2008) Clin Cancer Res , vol.14 , Issue.9 , pp. 2763-2767
    • Berthold, D.1    Pond, G.2    Roessner, M.3    de Wit, R.4    Eisenberger, M.5    Tannock, I.6
  • 2
    • 65349151253 scopus 로고    scopus 로고
    • Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease
    • Mostaghel E, Montgomery B, Nelson P. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009;27(3):251-257.
    • (2009) Urol Oncol , vol.27 , Issue.3 , pp. 251-257
    • Mostaghel, E.1    Montgomery, B.2    Nelson, P.3
  • 3
    • 79957443342 scopus 로고    scopus 로고
    • Abiraterone and increased survival in metastatic prostate cancer
    • de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005.
    • (2011) N Engl J Med , vol.364 , Issue.21 , pp. 1995-2005
    • de Bono, J.S.1    Logothetis, C.J.2    Molina, A.3
  • 4
    • 84866770294 scopus 로고    scopus 로고
    • Increased survival with enzalutamide in prostate cancer after chemotherapy
    • Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-1197.
    • (2012) N Engl J Med , vol.367 , Issue.13 , pp. 1187-1197
    • Scher, H.I.1    Fizazi, K.2    Saad, F.3
  • 5
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-422.
    • (2010) N Engl J Med , vol.363 , Issue.5 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 6
    • 84880428467 scopus 로고    scopus 로고
    • Alpha emitter radium-223 and survival in metastatic prostate cancer
    • Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369(3):213-223.
    • (2013) N Engl J Med , vol.369 , Issue.3 , pp. 213-223
    • Parker, C.1    Nilsson, S.2    Heinrich, D.3
  • 7
    • 77957682309 scopus 로고    scopus 로고
    • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    • de Bono J, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 2010;376(9747):1147-1154.
    • (2010) Lancet , vol.376 , Issue.9747 , pp. 1147-1154
    • de Bono, J.1    Oudard, S.2    Ozguroglu, M.3
  • 8
    • 79957497548 scopus 로고    scopus 로고
    • Expanding treatment options for metastatic prostate cancer
    • Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011;364(21): 2055-2058.
    • (2011) N Engl J Med , vol.364 , Issue.21 , pp. 2055-2058
    • Antonarakis, E.S.1    Eisenberger, M.A.2
  • 9
    • 84872078210 scopus 로고    scopus 로고
    • Abiraterone in metastatic prostate cancer without previous chemotherapy
    • Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-148.
    • (2013) N Engl J Med , vol.368 , Issue.2 , pp. 138-148
    • Ryan, C.J.1    Smith, M.R.2    de Bono, J.S.3
  • 10
    • 79953099043 scopus 로고    scopus 로고
    • Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm
    • Garcia J, Dreicer R. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Oncology (Williston Park) 2011;25(3):242-249.
    • (2011) Oncology (Williston Park) , vol.25 , Issue.3 , pp. 242-249
    • Garcia, J.1    Dreicer, R.2
  • 11
    • 84878601468 scopus 로고    scopus 로고
    • Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial
    • Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology 2013;81(6):1297-1302.
    • (2013) Urology , vol.81 , Issue.6 , pp. 1297-1302
    • Schellhammer, P.F.1    Chodak, G.2    Whitmore, J.B.3    Sims, R.4    Frohlich, M.W.5    Kantoff, P.W.6
  • 12
    • 84887055798 scopus 로고    scopus 로고
    • A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer
    • Small E, Lance R, Redfern C et al. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer. J Clin Oncol 2013;31:abstr 5047.
    • (2013) J Clin Oncol , vol.31
    • Small, E.1    Lance, R.2    Redfern, C.3
  • 13
    • 84882799782 scopus 로고    scopus 로고
    • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
    • Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24(7):1802-1807.
    • (2013) Ann Oncol , vol.24 , Issue.7 , pp. 1802-1807
    • Noonan, K.L.1    North, S.2    Bitting, R.L.3    Armstrong, A.J.4    Ellard, S.L.5    Chi, K.N.6
  • 14
    • 84888852048 scopus 로고    scopus 로고
    • Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone
    • Schrader A, Boegemann M, Ohlmann C et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65(1):30-36.
    • (2014) Eur Urol , vol.65 , Issue.1 , pp. 30-36
    • Schrader, A.1    Boegemann, M.2    Ohlmann, C.3
  • 15
    • 84882789820 scopus 로고    scopus 로고
    • Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
    • Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24(7):1807-1812.
    • (2013) Ann Oncol , vol.24 , Issue.7 , pp. 1807-1812
    • Loriot, Y.1    Bianchini, D.2    Ileana, E.3
  • 16
    • 4744366279 scopus 로고    scopus 로고
    • Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock I, de Wit R, Berry W et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-1512.
    • (2004) N Engl J Med , vol.351 , Issue.15 , pp. 1502-1512
    • Tannock, I.1    de Wit, R.2    Berry, W.3
  • 19
    • 84878961883 scopus 로고    scopus 로고
    • A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases
    • Lee RJ, Saylor PJ, Dror Michaelson M et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013;19(11):3088-3094.
    • (2013) Clin Cancer Res , vol.19 , Issue.11 , pp. 3088-3094
    • Lee, R.J.1    Saylor, P.J.2    Dror Michaelson, M.3
  • 20
    • 84880508629 scopus 로고    scopus 로고
    • Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    • Slovin SF, Higano CS, Hamid O et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013;24(7):1813-1821.
    • (2013) Ann Oncol , vol.24 , Issue.7 , pp. 1813-1821
    • Slovin, S.F.1    Higano, C.S.2    Hamid, O.3
  • 21
    • 80052468423 scopus 로고    scopus 로고
    • Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c
    • Saad F, Hotte S, North S et al. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 2011;17(17):5765-5773.
    • (2011) Clin Cancer Res , vol.17 , Issue.17 , pp. 5765-5773
    • Saad, F.1    Hotte, S.2    North, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.